Danish Zealand Pharma has presented positive results for its phase 2 study of the amylin analogue petrelintide for the treatment of overweight and obesity, but despite this, the company is backing away from its plans. #ZealandPharma #fetma #hälsa (translated)
www.di.se
Trots positiv fas 2-studie backar läkemedelsbolaget
